Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasm Metastasis 2Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 43pembrolizumab 36Paclitaxel 36Nivolumab 31Docetaxel 29Capecitabine 29Bevacizumab 29Oxaliplatin 28Fluorouracil 28Cisplatin 26Leucovorin 24Cyclophosphamide 23Radiosurgery 20Irinotecan 20Carboplatin 20aldesleukin 19Cetuximab 19Interleukin-2 16fludarabine phosphate 15fludarabine 15Pemetrexed 15Trastuzumab 14Magnetic Resonance Spectroscopy 14Ipilimumab 14Fulvestrant 14130-nm albumin-bound paclitaxel 14Prednisone 13Everolimus 13Radiotherapy 12Panitumumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasm Metastasis × LY2940680 × Clear all
NCT01226485 2019-09-13

A Study in Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
84 enrolled 22 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01919398 2019-09-11

A Study of LY2940680 in Japanese Participants With Advanced Cancers

Eli Lilly and Company

Phase 1 Completed
19 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡